Landgren, Ola
Sonneveld, Pieter
Jakubowiak, Andrzej
Mohty, Mohamad
Iskander, Karim S.
Mezzi, Khalid
Siegel, David S.
Funding for this research was provided by:
Amgen
Amgen
Article History
Received: 21 February 2019
Revised: 13 May 2019
Accepted: 20 May 2019
First Online: 24 July 2019
Compliance with ethical standards
:
: Dr Landgren has received research funding from the National Institutes of Health, U.S. Food and Drug Administration, Multiple Myeloma Research Foundation, International Myeloma Foundation, Leukemia and Lymphoma Society, Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm; has served on honoraria/advisory boards for Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees for clinical trials led by Takeda, Merck, Janssen. Dr Sonneveld received research funding from Janssen, Celgene, Amgen, Karyopharm, SkylineDx, Takeda, and Novartis; and received personal fees from Janssen, Celgene, and Amgen. Dr Jakubowiak repots consultancy, honoraria, and membership on an entity’s Board of Directors or Advisory Committees fees from Amgen, ABBVIE, BMS, Celgene, Janssen, Karyopharm, Millennium, Takeda, Sanofi, and SkylineDx. Dr Mohty has no disclosures to report. Dr Iskander and Dr Mezzi are employees of and own stock in Amgen, Inc. Dr Siegel reports honoraria and consulting or advisory role fees for Celgene, Amgen, Merck, Janssen, BMS, Takeda, and Karyopharm; speakers’ bureau participation for Celgene, Amgen, Merck, Janssen, BMS, and Takeda; and research funding from Celgene.